Abbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Abbott
Abbott's Infinity™ DBS is the first FDA approved directional Deep Brain Stimulation (DBS) system to allow targeting of a specific area of the brain that is critical to motor functions

Abbott today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication for the company's Infinity™ Deep Brain Stimulation (DBS) system to include the targeting of an area of the brain called the internal globus pallidus (GPi). The GPi plays an integral role in the motor function and can be targeted with DBS to improve the symptoms of Parkinson's disease not adequately controlled by medication.

With this approval, Abbott's Infinity DBS is now the only directional DBS system approved for all major targets used to treat movement disorders, Parkinson's disease and Essential Tremor: the subthalamic nucleus (STN), ventral intermediate nucleus (VIM) and GPi. It is the world's first and only DBS system operating in these indications on an iOS software platform with Bluetooth® wireless technology. Clinicians can streamline the programming process with an iPad mini device using Abbott's new Informity™ Programming feature to become more efficient in their practice and achieve optimal outcomes with directional leads. Patients can discreetly manage their symptoms with their Infinity DBS System iPod touch controller.

"The internal segment of the global pallidus, or GPi, is a well-established valuable DBS target for the management of the motor signs associated with Parkinson's disease, and is a preferred target for many patients, particularly for those with troublesome medication-induced dyskinesia," said Jerrold Vitek, M.D., Ph.D., head of the Neurology Department, director of the Neuromodulation Research Program, and centre director of the University of Minnesota Udall Center of Excellence for Parkinson's Research. "This approval expands the options for patients to tailor treatment to their unique needs, with the added benefits of being able to target precise areas and utilizing a patient-friendly iOS device."

Abbott's Infinity DBS system with directional leads provides directed stimulation to areas of the brain to optimize patient outcomes and limit side effects. The platform's future-ready technology has the ability to seamlessly upgrade the approved capabilities and new therapy features of the Infinity DBS system through simple, over-the-air updates.

Tags : #abbott #fda #deep #brain #simulation #parkinsondisease #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Patient Safety Is a Business Priority for Indian HospitalsNovember 10, 2026
Reducing ED Wait Times Through Smarter Hospital DesignNovember 10, 2026
Maternal Mental Health: Integrating Emotional Wellbeing Into Postnatal CareNovember 10, 2026
Occupational Health for Healthcare Workers: Preventing Musculoskeletal StrainNovember 10, 2026
Sleep Health in India: Recognising the Public Health Impact of Sleep DisordersNovember 06, 2026
Childhood Hearing Screening: Linking Early Detection With Timely SupportNovember 06, 2026
Low-Dose Imaging in India: Accuracy Meets SafetyNovember 06, 2026
Synthetic Health Data: Powering the Future of Medical AINovember 06, 2026
AI and Clinical Trials: How ML Is Changing Patient RecruitmentNovember 05, 2026
Photon-Counting CT: What Indian Hospitals Need to KnowNovember 05, 2026
Rare Diseases in India: Navigating Diagnosis, Support and Long-Term CareNovember 05, 2026
Oral Health and Systemic Health: The Case for Routine Dental IntegrationNovember 05, 2026
KIMS Hospitals Takes Another Major Step Forward in Cancer Care with Advanced TrueBeam TechnologyNovember 04, 2026
SRM Medical College Hospital and Research Centre Hosts National Conference on Translational Regenerative Biology and Bioengineering – TRBB 2026November 04, 2026
15-Month-Old Russian Baby Avoids Lung Transplant Following Treatment at MGM HealthcareNovember 04, 2026
Why Diabetes Care Must Go Beyond Blood Sugar ControlNovember 04, 2026
Sri Sathya Sai Heart Hospital Successfully Organises Free Heart Camp, Screening for 550 Patients in Dehradun, UttarakhandNovember 04, 2026
Expert Quote | Rising Air Pollution in Delhi | Agilus DiagnosticsNovember 04, 2026
Healthcare AI Safety Officers: India's New Leadership NeedNovember 04, 2026
Next-Generation Medical Imaging: Beyond Traditional ScansNovember 04, 2026